MPM Oncology Impact Management »

Zentalis Pharmaceuticals shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Zentalis Pharmaceuticals (ZNTL) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Zentalis Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Zentalis Pharmaceuticals held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Zentalis Pharmaceuticals by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $5.9M 1.5M 4.09
2024-03-31 $24M 1.5M 15.76

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Insmed Incorporated Common (INSM)
Olema Pharmaceuticals Common (OLMA)
iTeos Therapeutics Common (ITOS)
Crinetics Pharmaceuticals Common (CRNX)
Madrigal Pharmaceuticals Common (MDGL)
Iovance Biotherapeutics Common (IOVA)
Natera Common (NTRA)
Mirum Pharmaceuticals Common (MIRM)
Ultragenyx Pharmaceutical Common (RARE)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Guardant Health Common (GH)
Disc Medicine Common (IRON)
Alkermes Common (ALKS)
Edgewise Therapeutics Common (EWTX)

View all positions for MPM Oncology Impact Management

Top funds holding Zentalis Pharmaceuticals

Matrix Capital Management Company
Eventide Asset Management
Vanguard Group
BlackRock
BlackRock
Decheng Capital
State Street Corporation
Citadel Advisors
Morgan Stanley
PRIMECAP Management Company
MPM Oncology Impact Management
Geode Capital Management
D. E. Shaw & Co
Woodline Partners
Two Sigma Investments

View all funds holding Zentalis Pharmaceuticals